A CDK1
A CDK2
E CDK2
Extent of Rb
phosphorylatio
n
dephosphorylation
D CDK4/6
Target of CDK4/6
inhibitors
hyperphosphorylati
on
Inactivates Rb
and allows
progression
p16
INK4a
Preclinical predicator of sensitivity
- High Cyclin D1
- High Rb
- Low p16
Paloma 1:
- Cyclin D1 amplification or loss of
p16 unable to select group who
benefits
Paloma 3:
-
ER/PR status not predictive
-
PIK3CA mutations not predictive
-
ESR1 mutations not predictive
Finn, et al. Breast Cancer Res. 2009. Finn, et al. Lancet Oncol. 2015, Cristofinalli, et al Lancet Oncol 2016
Biomarker analysis
